Overview

TLC399 (ProDex) in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)

Status:
Completed
Trial end date:
2019-02-04
Target enrollment:
Participant gender:
Summary
Randomized, double-masked trial designed to investigate the use of TLC399 (ProDex) in subjects with macular edema due to CRVO or BRVO.
Phase:
Phase 2
Details
Lead Sponsor:
Taiwan Liposome Company